Ozempic ‘microdosing’ is new weight-loss trend
The Washington Post on MSN9d
FDA approves weight-loss drug Zepbound to treat sleep apneaThe Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
HealthDay on MSN1d
Some GLP-1s Achieve More Weight Loss Than Others: StudyBy comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...
Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...
In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...
News Nation on MSN10d
FDA approves Zepbound for sleep apnea in obese adultsZepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric Balloon, a swallowable, procedureless intragastric balloon, in adults with obesity.
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback